Publications by authors named "T Bieber"
Article Synopsis
- Treg impairment is linked to chronic inflammatory diseases, and the study explores the use of a new medication, rezpegaldesleukin (REZPEG), for restoring Tregs in patients with atopic dermatitis and psoriasis.
- Two trials showed that REZPEG is safe and well-tolerated, with effective dosing leading to significant improvements in disease severity scores after treatment.
- Patients who received the higher dose exhibited lasting benefits, such as significant EASI score improvements and sustained Treg increases, indicating the potential for long-term control of these skin conditions without ongoing treatment.
Incidence of cardiovascular events in a population-based Danish cohort with atopic dermatitis.
J Allergy Clin Immunol Glob
November 2024
Article Synopsis
- The study aimed to investigate the incidence of venous thromboembolism (VTE) and cardiovascular disease risk factors in patients with atopic dermatitis (AD) compared to healthy controls in Denmark from 2000 to 2018.
- Results showed similar rates of VTE, deep vein thrombosis (DVT), and pulmonary embolism (PE) between AD patients and healthy counterparts, although older AD patients (65+) had a higher VTE rate.
- Overall, while cardiovascular event rates were comparable, specific risk factors related to atherosclerotic cardiovascular disease (ASCVD) increased the risks for VTE, malignancies, and major adverse cardiovascular events (MACE), highlighting the need for ongoing patient monitoring.
The paradigm shift in drug development for atopic dermatitis: Addressing the variables of the equation leading to disease modification.
Ann Allergy Asthma Immunol
October 2024
Article Synopsis
- Recent advances in understanding atopic dermatitis (AD) mechanisms have led to the development of new therapies that aim for long-term disease modification rather than just temporary symptom relief.
- * A shift from a one-size-fits-all approach to precision medicine is needed, reflecting the complexity of AD by focusing on individualized treatment based on specific biomarkers.
- * The review discusses the scientific basis for these new strategies and outlines important factors for designing clinical trials aimed at achieving long-term remission in AD patients.
Article Synopsis
- - Atopic dermatitis (AD) is a common inflammatory skin condition that significantly affects patients' quality of life, with traditional treatments often having limited effectiveness and safety issues.
- - New biologic therapies aim to specifically target immune pathways involved in AD, including various interleukins and the OX40-OX40L axis, offering potential improvements in treatment efficacy and safety compared to conventional methods.
- - Emerging treatments, such as bispecific antibodies and thymic stromal lymphopoietin inhibitors, show promise in managing AD symptoms, but further long-term studies are needed to validate their effectiveness and safety in real-world settings.